Aviragen Therapeutics (AVIR) Tops Q3 EPS by 6c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q3 EPS of ($0.40), $0.06 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• General Mills beats estimates as cost savings offset volumes
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance